NIH Mechanistic Evaluation of Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33)

Source-based overview

NIH Mechanistic Evaluation of Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33) is a biomedical research grant from U.S. National Institutes of Health. Phased research identifying and validating modifiable mechanisms and therapeutic targets in HIV-associated CNS complications. It focuses on HIV; CNS outcomes; therapeutic targets; mechanistic research and is relevant to United States organisations. The recorded deadline or key date is Posted 30 Sep 2026; closes 28 Oct 2027. Applicants should review the official page for the complete eligibility rules, required documents, assessment criteria, funding conditions, deadline time zone and submission route.

Eligibility

Eligible applicants and locations: United States organisations. Confirm any institutional, citizenship, career-stage and partnership requirements on the official call page.

Funding and benefits

Award details in NOFO

See the official call page for funding and support details

Themes and supported activities

HIV; CNS outcomes; therapeutic targets; mechanistic research

Biomedical Research Grant

United States organisations

Deadline and timeline

Posted 30 Sep 2026; closes 28 Oct 2027: Posted 30 Sep 2026; closes 28 Oct 2027: Oct 28, 2027.

Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.

How to apply

Open the official call page, confirm the current requirements and deadline time zone, prepare the requested documents and submit through the funder or organiser's stated route.

Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.